[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100528839":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":65,"collaborators":26,"id":69,"slug":26,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":26,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":26,"enrollmentInfo":77,"targetDuration":26,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":49,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Qianfoshan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: bupivacaine hydrochloride","ACTIVE_COMPARATOR","Group A: Patients in the control group received 20 mL of 0.5% bupivacaine hydrochloride (total dose, 100 mg).",[13],"Drug: Group A: bupivacaine hydrochloride;",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B: liposomal bupivacaine and bupivacaine hydrochloride","EXPERIMENTAL","Patients in the intervention group received a mixture of 10 mL of 1.33% liposomal bupivacaine (133 mg) and 10 mL of 0.5% bupivacaine hydrochloride.",[19],"Drug: GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;","Group B::Patients in the intervention group received a mixture of 10 mL of 1.33% liposomal bupivacaine (133 mg) and 10 mL of 0.5% bupivacaine hydrochloride.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Group A: bupivacaine hydrochloride;","Group A:Patients in the control group received 20 mL of 0.5% bupivacaine hydrochloride (total dose, 100 mg).",[9],[32],{"name":33,"affiliation":34,"role":35},"Sun Y tao, PH.D","Shandong First Medical University","STUDY_CHAIR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"yong t Sun, PH.D","CONTACT","18660795201","sunyongtao1979@163.com",{"name":43,"role":39,"phone":44,"phoneExt":26,"email":45},"jian bo Wu, PH.D","18560083793","jianbowu@126.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University","RECRUITING","Jinan","Shandong","250014","China",{"type":55,"coordinates":56},"Point",[57,58],116.99722,36.66833,{"lat":58,"lon":57},[61,63],{"name":62,"role":39,"phone":40,"phoneExt":26,"email":41},"yong T Sun, PH.D",{"name":64,"role":39,"phone":40,"phoneExt":26,"email":41},"yong T Sun",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Yongtao Sun","Professor","100528839",false,"NCT06165991","Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain","The Effect of Bupivacaine Liposome Combined With Bupivacaine Hydrochloride on Thoracic Paravertebral Nerve Block for Postoperative Pain After Thoracoscopic Lung Surgery","Inclusion Criteria:\n\n* 1\\) Age ≥18 years old;\n\n  2\\) Patients undergoing unilateral initial thoracoscopic lobectomy under general anesthesia (TV or robot-assisted);\n\n  3\\) American Society of Anesthesiologists (ASA) Grade I - III;\n\n  4\\) Voluntarily participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n* 1\\) Pregnant or lactating women;\n\n  2\\) Pulmonary wedge-shaped resection;\n\n  3\\) ≥2 thoracic drainage tubes;\n\n  4\\) Abnormal liver function: ALT and\u002For AST\\>2×ULN, or\n\nTBIL≥1.5×ULN;\n\n5\\) Renal function impairment (serum creatinine \\>176μmol\u002FL), or received dialysis treatment within 28 days before surgery;\n\n6\\) Participate in another research trial involving an investigational drug within 6 months;\n\n7\\) A history of drug or alcohol abuse;\n\n8\\) Long-term use of opioids (more than 3 months or more than 5 mg daily morphine equivalent per day for 1 month);\n\n9\\) History of allergy to local anesthetics or one of the investigational drugs;\n\n10\\) Uncontrolled mental or neurological symptoms.","ALL","18 Years",{"count":78,"type":79},496,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","I. Research purpose\n\n1.1 Main Objective: To investigate the efficacy and safety of bupivacaine liposome thoracic paravertebral nerve block for postoperative analgesia after thoracoscopic lobectomy\n\n1.2 Exploratory Objective: To investigate the noninferiority of bupivacaine liposomes in thoracic paravertebral nerve block with standard bupivacaine",[85,86,87],"Thoracic Paravertebral Block","Postoperative Analgesia","Thoracoscopic Lobectomy",[89,90,91,92],"liposomal bupivacaine(LB)","Thoracic paravertebral nerve block","Postoperative analgesia","thoracoscopic lobectomy","2026-01-07",{"date":95,"type":96},"2026-01-09","ACTUAL",{"date":98,"type":96},"2024-06-01",{"date":100,"type":79},"2026-01-31",{"name":67,"class":6},1]